Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies

Overview of attention for article published in Nature Communications, February 2026

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user
reddit: 2 Redditors

bluesky: 1 Bluesky user

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 1 Bluesky users, with an upper bound of 111 followers.

New #ARTNetPublication: A study by Dr. Trever Bivona and colleagues reveals that the pan-RAF inhibitor exarafenib shows strong activity against BRAF Class II/III NSCLC, a population with no approved targeted therapies and representing ~65% of BRAF-mutan…

#ARTNetPublication A new paper in Nature Comms by Dr. Trever Bivona shows that exarafenib, a pan-RAF inhibitor, has strong activity against BRAF Class II/III NSCLC, mutations that make up ~65% of BRAF-mutant cases and currently lack approved therapies. …

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.